PMID- 23819551
OWN - NLM
STAT- MEDLINE
DCOM- 20140311
LR  - 20220318
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 112
IP  - 8
DP  - 2013 Dec
TI  - Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors 
      of MPs (TIMPs), and bladder cancer susceptibility.
PG  - 1207-14
LID - 10.1111/bju.12230 [doi]
AB  - OBJECTIVES: To elucidate genetic polymorphisms of the matrix metalloproteinases 
      (MMPs) MMP1 (rs1799750), MMP2 (rs243865), MMP9 (rs3918242), MMP12 (rs2276109) and 
      tissue inhibitors of MMPs (TIMPs) TIMP1 (rs2070584) and TIMP3 (rs9619311) genes 
      that may be involved in susceptibility to bladder cancer (BC). PATIENTS AND 
      METHODS: We enrolled 241 patients with BC and 199 controls. Genomic DNA samples 
      were extracted from peripheral blood and polymorphisms were analysed by 
      high-resolution melting analysis and by real-time polymerase chain reaction using 
      TaqMan fluorescent probes. RESULTS: Of the six evaluated polymorphisms of MMPs 
      and TIMPs, only one was found to be associated with BC risk. There was a 
      significant difference for MMP1 (rs1799750) 2G/1G+1G/1G genotype (odds ratio [OR] 
      0.62, 95% confidence interval [CI] 0.39-0.98; P = 0.042). Additionally, there was 
      a joint effect of this genotype on BC risk among 'ever smokers' (OR 0.51, 95% CI 
      0.28-0.89; P = 0.019), but not in 'never smokers'. The combined genotype MMP2 
      -1306C/T (rs243865) allele T with MMP9 -1562C/T (rs3918242) allele T was found to 
      increase BC risk (OR 2.00, 95% CI 1.10-3.62; P = 0.022). CONCLUSIONS: Our results 
      suggest that genetic variations in five polymorphisms of MMPs and TIMPs are not 
      associated with a high risk of BC. Only MMP1 polymorphism may be related to the 
      risk of BC, notably in 'ever smokers'. Our study suggests that the effects of 
      polymorphisms of MMPs and TIMPs on BC risk deserve further investigation.
CI  - (c) 2013 The Authors. BJU International (c) 2013 BJU International.
FAU - Wieczorek, Edyta
AU  - Wieczorek E
AD  - Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational 
      Medicine, Lodz, Poland.
FAU - Reszka, Edyta
AU  - Reszka E
FAU - Jablonowski, Zbigniew
AU  - Jablonowski Z
FAU - Jablonska, Ewa
AU  - Jablonska E
FAU - Krol, Magdalena Beata
AU  - Krol MB
FAU - Grzegorczyk, Adam
AU  - Grzegorczyk A
FAU - Gromadzinska, Jolanta
AU  - Gromadzinska J
FAU - Sosnowski, Marek
AU  - Sosnowski M
FAU - Wasowicz, Wojciech
AU  - Wasowicz W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130702
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (TIMP1 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Aged
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 1/*genetics
MH  - Odds Ratio
MH  - Poland/epidemiology
MH  - *Polymorphism, Single Nucleotide
MH  - Real-Time Polymerase Chain Reaction
MH  - Smoking/*adverse effects/epidemiology
MH  - Tissue Inhibitor of Metalloproteinase-1/*genetics
MH  - Urinary Bladder Neoplasms/epidemiology/*genetics
OTO - NOTNLM
OT  - MMP
OT  - TIMP
OT  - bladder cancer
OT  - case-control study
OT  - genetic polymorphism
OT  - susceptibility
EDAT- 2013/07/04 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/07/04 06:00
PHST- 2013/07/04 06:00 [entrez]
PHST- 2013/07/04 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.1111/bju.12230 [doi]
PST - ppublish
SO  - BJU Int. 2013 Dec;112(8):1207-14. doi: 10.1111/bju.12230. Epub 2013 Jul 2.